69 results about "Influenza A antigen" patented technology

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided.

Disclosed is a method for increasing vaccine potency whereby a subject's immune system is first primed with an Ii-Key hybrid peptide construct before the subject subsequently receives a vaccine for a pathogen of interest. The vaccine may be comprised of a protein or portion thereof that is encoded by the genome of the pathogen. The vaccine may also be a DNA vaccine comprised of DNA encoding a protein of the pathogen. The Ii-Key hybrid peptide construct includes the LRMK residues of Ii-Key protein and an MHC Class II epitope of the protein or portion thereof which is used in the vaccine. The Ii-Key construct may be administered in the form of a nucleic acid construct encoding the Ii-Key hybrid peptide. Priming with Ii-Key peptides enhances the immunogenicity of rHA protein and HA and HIV DNA vaccines. Methods are described relating to the use of Ii-Key hybrid constructs in vaccine protocols wherein the pathogen is HIV or Influenza A, including H5N1. Methods and compositions are described wherein the MHC Class II epitope of the Ii-Key hybrid is hemagglutinin encoded by Influenza A or the Gag protein encoded by HIV.

The invention provides a test kit for detecting nucleic acid of respiratory tract pathogens. The kit comprises a CRISPR-Cas detection system: crRNA, a primer pair, Cas protein and a nucleic acid probethat are described in the invention. The invention further provides a detection method of the nucleic acid of the respiratory tract pathogens, a combination of the crRNA and the primer pair and application of the combination. The test kit and the detection method disclosed by the invention can be used for directly observing results by naked eyes without depending on a large instrument, and detection can be realized under a mild condition, so that the detection is more convenient; the test kit and the detection method provided by the invention can be used for efficiently and rapidly detecting/diagnosing the respiratory tract pathogens (such as flu A, flu B and COVID-19), have relatively high specificity and sensitivity, and can be used for detecting and screening the respiratory tract pathogens, for example, rapidly distinguishing various respiratory tract pathogens including the flu A, the flu B and the COVID-19.

Provided herein are formulations containing copper ions and methods of treating underlying infections and conditions caused by coronavirus, particularly COVID-19, and influenzas, particularly influenza A and/or influenza B using such formulations. Methods of treating the underlying viruses and their resultant conditions using topical copper ion treatments are provided. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension may be combined with various carriers to form the copper ion treatment including creams or solutions. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.

The invention discloses a corona virus disease 2019 screening method and system based on deep learning. The corona virus disease 2019 screening method comprises the steps: detecting a lung lesion areaof CT by using a deep learning detection model, and conveying the lung lesion area of CT into a three-classification network, wherein three classifications comprise COVID-19, influenza A and non-infection symptoms; and through calculation processing, outputting a CT diagnosis result and a disease probability. According to the method, based on deep learning, characteristics of CT images are automatically learned to distinguish COVIDI-19, influenza A and healthy people, so that the method is high in accuracy, the overall accuracy of current testing reaches 86.7%, the diagnosis speed is high, and only 30-60 S is needed for one set of CT according to different slice numbers; and a user can upload a CT image file and calculate and output a CT diagnosis result and the disease probability through the corona virus disease 2019 screening system, so that operation is convenient, the speed is high, and the detection rate of COVID-19 is greatly increased.

The present invention provides for pharmaceutical compositions comprising pancreatic enzyme preparations (PEPs) with viral infectivity reduced below significant levels and having high enzymatic activity. The PEPs can comprise lipases, proteases, amylases, non-enveloped viruses (e.g., porcine parvovirus (PPV), porcine circovirus type 2 (PCV-2), porcine encephalomyocarditis virus (EMCV)), and enveloped viruses (e.g., vesicular stomatitis virus (VSV), and influenza A (IFA)). The present invention also includes methods of treating pancreatic insufficiency by administering these pharmaceutical compositions and methods of making the same by treating the PEP with beta-propiolactone (BPL) to reduce viral infectivity.

The invention discloses a preparation method of an anti-influenza A H1N1 virus specific IgY and related formulations thereof. The method comprises the steps of preparing a plurality of types of complex antigens aiming at influenza A H1N1, using the complex antigens for immunizing laying hen, utilizing the immune egg yolk for preparing specific IgY crude extract dry powder, conducting purification, removing all types of bacterial virus by filtration, and then preparing the anti-variant influenza A H1N1 virus specific IgY, anti-influenza secondary infection bacterial specific IgY, or anti-variant influenza A H1N1 virus specific complex IgY. In addition, the invention makes the anti-variant influenza A H1N1 virus specific IgY into nanoliposomes, and the obtained nanoliposome anti-variant influenza A H1N1 virus specific IgY enhances healing efficacy. The anti-influenza A H1N1 virus specific IgY can be utilized for preparing various formulations which then can prevent and teat the influenza A H1N1 of human and animals fundamentally; and the invention is more convenient, more economic, safer and more effective than the control method used at the present time.

The invention provides a kit for detecting nucleic acid of respiratory tract pathogens. The kit comprises a CRISPR-Cas detection system: crRNA, Cas protein and a nucleic acid probe as shown in the invention. The invention also provides a detection method of the nucleic acid of the respiratory tract pathogen, a separated nucleic acid, crRNA, a primer pair and application thereof. The kit and the detection method disclosed by the invention do not depend on large instruments, enable the results to be directly observed by naked eyes, can realize detection under mild conditions, and are more convenient in detection; the kit and the detection method provided by the invention can be used for efficiently and quickly detecting/diagnosing respiratory pathogens (such as influenza A, influenza B and novel coronavirus); the kit is high in specificity and sensitivity, and can be used for detecting and screening respiratory pathogens, such as rapidly distinguishing various respiratory pathogens including influenza A, influenza B and novel coronavirus.

The invention discloses a multi-fluorescent PCR rapid detection kit for novel coronavirus, influenza A virus and influenza B virus. The kit comprises freeze-dried solid RT-PCR Mix, liquid redissolution Buffer, freeze-dried solid positive control and freeze-dried solid negative control, wherein the freeze-dried solid RT-PCR Mix contains a primer group corresponding to primer sequences of a SARS-CoV-2 specific gene ORF1ab, an influenza A M gene, an influenza B M gene and a human reference gene RNAse P. The kit combines a multi-fluorescent quantitative PCR technology and a freeze-drying process, utilizes three pairs of special primers and human reference genes to amplify specific sequences of three pathogens in vitro, and performs real-time detection in combination with a fluorescent probe. The detection method is simple and convenient to operate, has low requirements for the operation level of detection personnel, and can detect three common respiratory pathogens at a time, the detection time and the detection cost are greatly saved, rapid screening of large-batch samples is realized, the whole detection process only takes 40 minutes to 1 hours, and results are accurate and reliable.

The invention discloses a traditional Chinese medicine composite preparation. The composite traditional Chinese medicine composite preparation comprises the raw medicines in parts by weight of 5-20 parts of poria cocos, 5-10 parts of licorice roots, 5-20 parts of fructus aurantii, 5-20 parts of platycodon roots, 10-20 parts of radix bupleuri, 15-50 parts of plaster stones, 10-20 parts of rhizoma anemarrhenae, 10-20 parts of hogfennel roots, 10-20 parts of notopterygium incisum roots, 10-20 parts of rhizoma cimicifugae, 10-20 parts of divaricate saposhnikovia roots, 10-20 parts of fineleaf schizonepeta herbs, 10-20 parts of ligusticum wallichii, 10-30 parts of radix puerariae, 5-10 parts of mint, 15-30 parts of honeysuckle flowers, 15-30 parts of fructus forsythiae, 10-20 parts of wrinkledgianthyssop herbs, 5-15 parts of herba ephedrae and 10-30 parts of swordlike atractylodes rhizomes. The traditional Chinese medicine composite preparation has the effects of expelling pathogenic factors from the exterior, relieving exterior syndromes, promoting the dispersing function of the lung, dissipating dampness, removing toxin, clearing away the lung and the like, can be used for treating viral pneumonia caused by influenza A, and can have obvious healing effects on typical symptoms of the influenza A, including fever, discomfort or pain in throat, cough and the like. According to the traditional Chinese medicine composite preparation, common traditional Chinese medicines are used as raw materials, the advantage that the traditional Chinese medicines are low in toxic and side effects is exerted, and the traditional Chinese medicine composite preparation is safe, effective, cheap, and easy to broadly generalize, and has high clinical application value.

Poly ICLC or liposome-encapsulated Poly ICLC (LE Poly ICLC) in combination with antisense oligonucleotides (AS) act synergistically in post-exposure prophylaxis or therapy of influenza infections, especially H5N1 virus infections.

The invention provides multiple primers and a kit for rapidly detecting influenza A, influenza B and novel coronavirus and relates to the field of molecular biological detection technology and molecular diagnosis. According to the real-time fluorescence PCR method based on reverse transcription heat convection, a specific multiple rapid diagnosis system is developed for respective conserved regions of influenza A virus, influenza B virus and novel coronavirus, and meanwhile, human endogenous genes are detected for sample quality control. The multiple primers and the kit are good in specificityand high in sensitivity, have the characteristics of simplicity, convenience, quickness and practicability, and meet detection requirements of influenza A viruses, influenza B viruses and novel coronaviruses in entry and exit and on-site environments.

Methods for the rapid detection of the presence or absence of SARS-CoV-2 in biological or non-biological samples are described. These methods are adapted to be performed rapidly in a point-of-care setting. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Specifically, primers and probes targeting SARS-CoV-2 are provided that are designed for the detection of this target. Additionally, kits and reaction vessels containing primers and probes targeting SARS-CoV-2 are provided. Additionally, methods, kits and reaction vessels for the simultaneous rapid detection of the presence or absence of SARS-CoV-2, influenza A, and influenza B in biological or non-biological samples are described.

The invention provides a COVID-19 and influenza pneumonia preliminary screening method and system and equipment. Based on clinical symptom signs, blood routine examination indexes and blood biochemical examination indexes of a patient, a tool capable of rapidly identifying and distinguishing the COVID-19 and the influenza A pneumonia is constructed; and finally, an optimal model and a suboptimal model are constructed according to the diagnosis capability. The optimal model has a rapid and accurate preliminary screening capability; the suboptimal model provides a preliminary screening identification tool constructed based on personal symptom signs and blood routine examination when underdeveloped area medical resources cannot undertake blood biochemical detection, so that assistance is provided for effective investment of medical and public health prevention and control resources.

The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase possessing endonuclease activity, wherein said PA subunit is from Influenza A 2009 pan-demic H1N1 virus or is a variant thereof. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting. This invention also relates to compounds which are able to modulate, preferably to inhibit, the endonuclease activity of the PA subunit polypeptide fragment or variant thereof of the present invention and pharmaceutical compositions comprising said compounds for the treatment of disease conditions caused by viral infections with viruses of the Orthomyxoviridae family, Bunyaviridae family and/or Arenviridae family, preferably caused by viral infections with Influenza A 2009 pandemic H1N1 virus. Preferably, said compounds are identifiable by the methods disclosed herein or said pharmaceutical compositions are producible by the methods disclosed herein.

The invention provides a general type DNA vaccine for influenza A, and a preparation method and application of the general type DNA vaccine for influenza A. Genes of three fusion proteins are constructed through highly-conservative sequences of an HA protein, an M2e protein and a NP protein of influenza viruses, then the genes are cloned to a pCDNA3.1(+) carrier, and three recombinant DNA vaccinespcDNA3.1-sHA, pcDNA3.1-mHA and pcDNA3.1-cHA are constructed. The DNA vaccine can be used for respects of preventing influenza homologous viruses, influenza heterogenesis viruses and the like of lactation type wild animals of tigers and the like. The DNA vaccine disclosed by the invention is simple in preparation method, low in cost, good in immunogenicity and good in cross protection, can meet preparation requirements for large-scale influenza vaccinations, is food in biological safety, and can arouse immunity of organisms to various influenza viruses.

The invention discloses an influenza A (H1N1) hemagglutinin (HA) antigen, and a purpose of the antigen in the preparation of a detecting reagent of the influenza A (H1N1) HA antibody. According to the invention, with bioinformatical technologies, analysis is carried out upon existing influenza A (H1N1) HA sequences, and 5 antigen segments are selected for cloning expressions. Reactions of the HA antigens are detected through serum of influenza A (H1N1) vaccinated people. An indirect enzyme-linked immunosorbent assay (Elisa) method is established for detecting the influenza A (H1N1) HA antibodies, and the antibody types are further identified. According to the invention, influenza A (H1N1) virus is not contacted, such that the safety is ensured. The antigen can be used in crowd influenza A(H1N1) epidemiology and in the verification of vaccine protection effect.

The present invention relates to the murine monoclonal antibody (mAb) 11B9 and to mAb 62 each of which target major neutralizing epitopes of influenza A H7 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H7 influenza using murine mAb 11B9, mAb 62 or fragments thereof. The present invention further relates to methods and kits for determining, identifying and/or quantifying (a) influenza A hemagglutinin in a sample or vaccine or (b) an antibody against influenza A hemagglutinin.